Dr Stergios Vradelis and colleagues assessed the correlation of Chromogranin A (CgA) with inflammatory bowel disease (IBD) activity and responsiveness to medical therapy.
The research team conducted a prospective observational study in 56 patients with moderate ulcerative colitis (UC) or Crohn’s disease (CD), 17 patients with irritable bowel syndrome and predominant diarrhea (IBS-D) and 40 healthy volunteers.
IBD patients were treated by biologics or conventional agents and were classified according to their treatment in two groups.
|69% patients were in remission during the 4-week posttreatment period|
|Scandanavian Journal of Gastroenterology|
Serum CgA was measured at baseline and 4-week posttreatment period.
The research team found that serum CgA was significantly higher in IBD patients than in those with IBS-D or healthy volunteers.
Furthermore, serum CgA was markedly increased in CD patients than in UC patients.
The team noted that CgA value was significantly reduced in ‘biologic’ group at 4-week posttreatment period, while 72% of patients were already in remission during that time.
In contrast, CgA value was significantly increased in the ‘conventional’ treatment group between the two visits, although 69% patients were in remission during the 4-week posttreatment period.
Dr Vradelis' team concludes, "CgA appears to be a reliable marker of disease activity in IBD patients and especially in those who received biologic therapy."
"IBS-D patients presented normal CgA values."